For Patients and Caregivers

VEN+AZA efficacy

OS

VIALE-A: A randomized (2:1), double-blind, placebo-controlled, multicenter, phase 3 study that evaluated the efficacy and safety of VENCLEXTA (venetoclax tablets) in combination with azacitidine (VEN+AZA; N=286) vs placebo with azacitidine (PBO+AZA; N=145) in adults with newly diagnosed AML who were ≥75 years of age, or had comorbidities (see baseline characteristics) that precluded the use of intensive induction chemotherapy.1

View full study design.

VEN+AZA demonstrated superior overall survival (OS) vs AZA1

PRIMARY ENDPOINT: overall survival

Median OS was extended by 5.1 months in patients treated with VEN+AZA vs AZA

  • Median follow-up for OS was approximately 1.7 years (20.5 months, range: <0.1-30.7 months)3
    • Median follow-up was estimated using reverse Kaplan-Meier methodology 

AZA=azacitidine; HR=hazard ratio; mOS=median overall survival; OS=overall survival; PBO=placebo; VEN=VENCLEXTA.

Remission and Transfusion Independence

Almost 3x more remissions,* longer mDOR observed with VEN+AZA vs AZA1

SECONDARY ENDPOINTS: CR, CR+CRh1,3
pre-specified exploratory endpoints: mDOCR,† mDOCR+CRh†

Powerful, durable remissions1

  • CR, 95% CI: (31, 43); P<0.001 
  • CR+CRh, 95% CI: (59, 70); P<0.001 
  • CR, 95% CI: (12, 25) 
  • CR+CRh, 95% CI: (16, 30) 

*Remission refers to CR+CRh.

DOCR (duration of CR) is defined as the number of days from the date of first response of CR to the date of earliest evidence of confirmed morphologic relapse, confirmed progressive disease, or death due to disease progression.1

DOCR+CRh (duration of CR+CRh) is defined as the number of days from the date of first response of CR+CRh (the first of either CR or CRh) to the date of earliest evidence of confirmed morphologic relapse, confirmed progressive disease, or death due to disease progression.1

Greater transfusion independence conversion and/or maintenance rates were observed with VEN+AZA vs AZA1

†Endpoints were not powered or tested to demonstrate a statistically significant difference between the treatment arms.

Transfusion independence was defined as no RBC and no platelet transfusion during any consecutive ≥56-day post-baseline period.1

Transfusion dependence was defined as requiring RBC or platelet transfusion at baseline (within 8 weeks prior to the first dose of study drug or randomization).3

CI=confidence interval; mDOR=median duration of response; mDOCR=median duration of complete remission; mDOCR+CRh=median duration of complete response and complete remission with partial hematologic recovery; RBC=red blood cell.

Long-Term Follow-Up

VIALE-A: long-term follow-up OS data on VEN+AZA vs AZA17

Median follow-up for OS was approximately 3.5 years (43.2 months, range: <0.1-53.4)17

Data cutoff date: December 1, 2021

  • The rates shown are estimated and can be unreliable due to a large number of patients censored at the tail end of the curve
  • The rates were not powered to demonstrate a statistically significant difference in survival rates
  • No conclusions of efficacy or safety can be drawn from these data

VIALE-A: exploratory post hoc subgroup analysis of dose schedule modifications in responders receiving ≥6 cycles of VEN+AZA17

‡In the VIALE-A clinical trial, following a dose interruption, if hematologic recovery was not achieved, VENCLEXTA could be reduced by 7 days to 21 days out of a 28-day cycle. 

This exploratory post hoc analysis was not powered to demonstrate statistical significance. No conclusions of efficacy or safety can be drawn from these data.

Subgroup Data

Remission rates in different subgroups5,16

Median follow-up: 20.5 months

OS data in the consolidated IDH1/2 group17

Median follow-up: 43.2 months

  • OS in IDH1/IDH2 was a pre-specified secondary endpoint. Subgroup analyses were not powered to demonstrate a statistically significant difference in OS. Small patient numbers in this subgroup can be a limitation of this analysis. No conclusions of efficacy or safety can be drawn from these data

Descriptive pre-specified analysis of OS in secondary and exploratory endpoints17

Median follow-up: 43.2 months

  • OS in the IDH1/2 and FLT3 subgroups was a pre-specified secondary endpoint. Other select biomarker subgroups (IDH1, IDH2, TP53, and NPM1), cytogenetic risk, age, and ECOG score were exploratory endpoints

Subgroup analyses were not powered to demonstrate a statistically significant difference in OS. Small patient numbers and lack of multiplicity adjustments for some subgroups can be a limitation of these analyses. No conclusions of efficacy or safety can be drawn from these data.

§The HR of OS was estimated using the stratified log-rank test and the Cox proportional hazards model for OS.

ECOG=Eastern Cooperative Oncology Group; FLT=fms-like tyrosine kinase; IDH=isocitrate dehydrogenase; NPM=nucleophosmin; n/N=total number of patients per total number of events; NR=not reached; TP53=tumor protein 53.

Patient-Reported Outcomes

Patient Reported Outcomes (PROs) were used to evaluate Quality of Life (QoL) among 1L AML patients in an exploratory, follow-up analysis of VIALE-A21

QoL measures may be used to assess AML treatment impacts on functioning and well-being. PRO questionnaires were collected on||:

Global Health Status


EORTC QLQ-C30 Questionnaire

Fatigue


PROMIS Fatigue Short Form 7a

Median follow-up was ~43.2 months (range: <0.1-53.4).17

||All questionnaires were collected on Day 1 of Cycle 1 and every other cycle for the duration of the trial.

PRO endpoints were evaluated based on time to deterioration (TTD)**

Number of days from baseline to the first worsening of ≥1 pre-established threshold

**TTD data does not capture improvements in PRO measure from baseline in responding patients. Patients without a baseline PRO measure were excluded from analysis. Deterioration events were based on the change from the baseline score only. TTD analyses were conducted for all patients in the full dataset with available data on ≥1 PRO measure from baseline to the given assessment.

EORTC QLQ-C3021

Global Health Status/Quality of Life (GHS/QoL) was evaluated in patients receiving VEN+AZA or AZA

  • In VIALE-A, patients rated their overall health on a scale from 1 (very poor) to 7 (excellent) over the past week using the GHS/QoL domain of the EORTC QLQ-C3021,22

Data limitations

  • The results were not powered to demonstrate a statistically significant difference in TTD; therefore, no formal inferences may be drawn
  • The defined thresholds may not correlate with clinically meaningful deterioration
  • The PRO measures are not validated in AML

Median Time to Deterioration23

  • Time to Deterioration was defined as the number of days from baseline to the first documented worsening of ≥10 points23,24

PROMIS Short Form 7a25

Impact of fatigue was evaluated in patients receiving VEN+AZA or AZA

  • In VIALE-A, patients rated their fatigue—specifically, how often they felt tired, exhausted, or lacked energy, as well as how fatigue affected their work, thinking, hygiene, and exercise—on a scale from 1 (never) to 5 (always) using the PROMIS Fatigue Short Form 7a21,25

Data limitations

  • The results were not powered to demonstrate a statistically significant difference in TTD; therefore, no formal inferences may be drawn
  • The defined thresholds may not correlate with clinically meaningful deterioration
  • The PRO measures are not validated in AML

Median Time to Deterioration23

  • Time to Deterioration was defined as the number of days from baseline to the first documented increase of ≥5 points for total score26

1L=first line; AML=acute myeloid leukemia; EORTC QLQ-C30=European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; IQR=interquartile range; PRO=patient reported outcome; PROMIS=Patient-reported Outcome Measurement Information System; QoL=quality of life; RBC=red blood cell; TLS=tumor lysis syndrome; TP53=tumor protein 53; TTD=time to deterioration.

RWE

RWE ARC study: design

VEN+AZA ARC Initiative: an ongoing retrospective real-world analysis18,19

Data method

The AML Real-world EvidenCe (ARC) Initiative is an ongoing retrospective patient medical chart review from 10 US academic sites and 4 Israeli academic sites. While the ARC study population is broader, this subgroup analysis includes only patients from the population described in the next section

Population
  • 90 adult patients
  • Newly diagnosed with AML
  • Ineligible for intensive induction chemotherapy, defined as patients ≥75 years of age, or with one of the comorbidities of interest per the Ferrara criteria and physician judgment from the study primary investigator
  • Treated with VEN+AZA
  • No prior treatment on venetoclax
  • Median age of the study population was 76 years (range: 34-89), and 24% had secondary AML
Study period
  • VEN+AZA treatment started on April 11, 2016. Follow-up was until May 30, 2022
  • Median follow-up: 10.2 months
Study outcomes
  • CR rate: complete response rate was calculated among the 87 patients with available physician-reported response data documented in patient medical records
  • mOS: median OS was estimated by the Kaplan-Meier survival analysis to summarize time to death
ARC study limitations
  • Patients in this study were treated in academic centers and results may not be generalizable to AML patients treated in the community setting
  • Results in this study are based on information as recorded in patient charts by the treating physician, which may have been subject to potential data entry errors and differences in record keeping practices across the different centers included in this study. However, a series of data quality checks were performed to ensure that data values followed reasonable logics and expected ranges to alleviate data entry errors
  • The response rate in this study was reported as recorded by the physician in the patient chart, may be subject to physician interpretation; however, the European LeukemiaNet (ELN) 2017 guidelines were provided as a guidance for definition of responses in the electronic case report form. It is unknown whether the ELN guidelines were routinely used in real-world practice to assess response
  • Safety outcomes were not part of the study objectives, and this study was not powered to detect clinically meaningful changes in the safety endpoints

RWE ARC study: OS and CR18

Median follow-up of 10.2 months

VEN+AZA outcomes in newly diagnosed patients ineligible for chemotherapy18

Real-world data are observational in nature and are not based on controlled clinical studies. Results from this study may differ from those observed and are not in the VENCLEXTA Prescribing Information.

Safety icon

Safety Data

Review a summary of safety data for patients treated with VEN+AZA in the VIALE-A trial

 

Review Safety Data
NEXT: Efficacy in VEN + DEC

US-VENA-250092

Important Safety Information & Indication

Indication

VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Important Safety Information

Tumor Lysis Syndrome
  • Tumor lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients treated with VENCLEXTA.
  • VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase in all patients. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.
  • In patients with AML who followed the current 3-day ramp-up dosing schedule and the TLS prophylaxis and monitoring measures, the rate of TLS was 1.1% in patients who received VENCLEXTA in combination with azacitidine. In patients with AML who followed a 4-day ramp-up dosing schedule and the TLS prophylaxis and monitoring measures, the rate of TLS was 5.6% and included deaths and renal failure in patients who received VENCLEXTA in combination with low-dose cytarabine.
  • The risk of TLS is a continuum based on multiple factors, particularly reduced renal function, tumor burden, and type of malignancy.
  • Assess all patients for risk and provide appropriate prophylaxis for TLS, including hydration and anti-hyperuricemics. Monitor blood chemistries and manage abnormalities promptly. Employ more intensive measures (IV hydration, frequent monitoring, hospitalization) as overall risk increases. Interrupt dosing if needed; when restarting VENCLEXTA follow dose modification guidance in the Prescribing Information.
  • Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase, and requires VENCLEXTA dose reduction.
Neutropenia
  • In patients with AML, baseline neutrophil counts worsened in 95% to 100% of patients treated with VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine. Neutropenia can recur with subsequent cycles.
  • Monitor complete blood counts. Interrupt dosing for severe neutropenia. Resume at same dose then reduce duration based on remission status and first or subsequent occurrence of neutropenia. Consider supportive measures including antimicrobials and growth factors (e.g., G-CSF).
Infections
  • Fatal and serious infections such as pneumonia and sepsis have occurred in patients treated with VENCLEXTA. Monitor patients for signs and symptoms of infection and treat promptly. Withhold VENCLEXTA for Grade 3 and 4 infection until resolution and resume at same dose.
Immunization
  • Do not administer live attenuated vaccines prior to, during, or after treatment with VENCLEXTA until B-cell recovery occurs. Advise patients that vaccinations may be less effective.
Embryo-Fetal Toxicity
  • VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for 30 days after the last dose.
Increased Mortality in Patients with Multiple Myeloma when VENCLEXTA is Added to Bortezomib and Dexamethasone
  • In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with VENCLEXTA in combination with bortezomib plus dexamethasone is not recommended outside of controlled clinical trials.
Adverse Reactions
  • In patients with AML receiving combination therapy with azacitidine, the most frequent serious adverse reactions (≥5%) were febrile neutropenia (30%), pneumonia (22%), sepsis (excluding fungal; 19%), and hemorrhage (6%). The most common adverse reactions including hematological abnormalities (≥30%) of any grade were neutrophils decreased (98%), platelets decreased (94%), lymphocytes decreased (91%), hemoglobin decreased (61%), nausea (44%), diarrhea (43%), febrile neutropenia (42%), musculoskeletal pain (36%), pneumonia (33%), fatigue (31%), and vomiting (30%). Fatal adverse reactions occurred in 23% of patients who received VENCLEXTA in combination with azacitidine, with the most frequent (≥2%) being pneumonia (4%), sepsis (excluding fungal; 3%), and hemorrhage (2%).
  • In patients with AML receiving combination therapy with decitabine, the most frequent serious adverse reactions (≥10%) were sepsis (excluding fungal; 46%), febrile neutropenia (38%), and pneumonia (31%). The most common adverse reactions including hematological abnormalities (≥30%) of any grade were neutrophils decreased (100%), lymphocytes decreased (100%), white blood cells decreased (100%), platelets decreased (92%), hemoglobin decreased (69%), febrile neutropenia (69%), fatigue (62%), constipation (62%), musculoskeletal pain (54%), dizziness (54%), nausea (54%), abdominal pain (46%), diarrhea (46%), pneumonia (46%), sepsis (excluding fungal; 46%), cough (38%), pyrexia (31%), hypotension (31%), oropharyngeal pain (31%), edema (31%), and vomiting (31%). One (8%) fatal adverse reaction of bacteremia occurred within 30 days of starting treatment.
  • In patients with AML receiving combination therapy with low-dose cytarabine, the most frequent serious adverse reactions (≥10%) were pneumonia (17%), febrile neutropenia (16%), and sepsis (excluding fungal; 12%). The most common adverse reactions including hematological abnormalities (≥30%) of any grade were platelets decreased (97%), neutrophils decreased (95%), lymphocytes decreased (92%), hemoglobin decreased (63%), nausea (42%), and febrile neutropenia (32%). Fatal adverse reactions occurred in 23% of patients who received VENCLEXTA in combination with LDAC, with the most frequent (≥5%) being pneumonia (6%) and sepsis (excluding fungal; 7%).
Drug Interactions
  • Concomitant use with a P-gp inhibitor or a strong or moderate CYP3A inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Consider alternative medications or adjust VENCLEXTA dosage and monitor more frequently for adverse reactions. Resume the VENCLEXTA dosage that was used prior to concomitant use of a P-gp inhibitor or a strong or moderate CYP3A inhibitor 2 to 3 days after discontinuation of the inhibitor.
  • Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.
  • Avoid concomitant use of strong or moderate CYP3A inducers.
  • Monitor international normalized ratio (INR) more frequently in patients receiving warfarin.
  • Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
Lactation
  • Advise nursing women not to breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.
Females and Males of Reproductive Potential
  • Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for 30 days after the last dose.
  • Based on findings in animals, VENCLEXTA may impair male fertility.
Hepatic Impairment
  • Reduce the dose of VENCLEXTA for patients with severe hepatic impairment (Child-Pugh C); monitor these patients more frequently for signs of adverse reactions. No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.

Please see full Prescribing Information.

VENCLEXTA® and its design are registered trademarks of AbbVie Inc.

    • VENCLEXTA Prescribing Information.

      VENCLEXTA Prescribing Information.

    • Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed November 24, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

      Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed November 24, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

    • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.

      DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629.

    • Data on file, AbbVie Inc. ABVRRTI71211.

      Data on file, AbbVie Inc. ABVRRTI71211.

    • Data on file, AbbVie Inc. ABVRRTI71272.

      Data on file, AbbVie Inc. ABVRRTI71272.

    • Data on file, AbbVie Inc. ABVRRTI67697.

      Data on file, AbbVie Inc. ABVRRTI67697.

    • Data on file, AbbVie Inc. ABVRRTI71500.

      Data on file, AbbVie Inc. ABVRRTI71500.

    • CRESEMBA Prescribing Information.

      CRESEMBA Prescribing Information.

    • US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration website. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Updated June 5, 2023. Accessed May 1, 2024.

      US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration website. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Updated June 5, 2023. Accessed May 1, 2024.

    • Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281-2294.

      Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281-2294.

    • Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9(2):159-165.

      Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998;9(2):159-165.

    • Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60(6):666-675.

      Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 2013;60(6):666-675.

    • Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012:524308.

      Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012;2012:524308.

    • Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89(1):243-255.

      Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood. 1997;89(1):243-255.

    • Data on file, Genentech, Inc. August 2025.

      Data on file, Genentech, Inc. August 2025.

    • Data on file, AbbVie Inc. ABVRRTI73540.

      Data on file, AbbVie Inc. ABVRRTI73540.

    • Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615-624.

      Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615-624.

    • Data on file, AbbVie Inc. ABVRRTI74719.

      Data on file, AbbVie Inc. ABVRRTI74719.

    • Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997-999.

      Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27(5):997-999.

    • Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Oral abstract presented at: 64th ASH Annual Meeting and Exposition; December 10, 2022; New Orleans, Louisiana. https://clin.larvol.com/abstract-detail/ASH%202022/61249960

      Pratz KW, Jonas BA, Pullarkat V, et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Oral abstract presented at: 64th ASH Annual Meeting and Exposition; December 10, 2022; New Orleans, Louisiana. https://clin.larvol.com/abstract-detail/ASH%202022/61249960

    • Pratz KW, Panayiotidis P, Recher C, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12(4):71.

      Pratz KW, Panayiotidis P, Recher C, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12(4):71.

    • Questionnaires. EORTC Quality of Life. Accessed February 28, 2025. https://qol.eortc.org

      Questionnaires. EORTC Quality of Life. Accessed February 28, 2025. https://qol.eortc.org

    • Pratz KW, Lai C, Jones BA, et al. Venetoclax plus azacitidine delays deterioration of health-related quality of life in patients with acute myeloid leukemia: VIALE-A long-term follow up. Oral abstract presented at: European Hematology Association (EHA) 2023 Hybrid Congress; June 8-11 2023; Frankfurt, Germany.

      Pratz KW, Lai C, Jones BA, et al. Venetoclax plus azacitidine delays deterioration of health-related quality of life in patients with acute myeloid leukemia: VIALE-A long-term follow up. Oral abstract presented at: European Hematology Association (EHA) 2023 Hybrid Congress; June 8-11 2023; Frankfurt, Germany.

    • Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oneal. 1998;16(1):139-144.

      Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oneal. 1998;16(1):139-144.

    • PROMIS Cancer Fatigue Short Form. NIH HEAL Initiative. Accessed February 28, 2025. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf

      PROMIS Cancer Fatigue Short Form. NIH HEAL Initiative. Accessed February 28, 2025. https://www.eortc.org/app/uploads/sites/2/2018/08/Specimen-QLQ-C30-English.pdf

    • Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507-516.

      Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64(5):507-516.

    • Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:1-14.

      Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:1-14.

    • Percival ME, Lai C, Estey E, Hourigan CS. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017;31(4):185-192.

      Percival ME, Lai C, Estey E, Hourigan CS. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Rev. 2017;31(4):185-192.

    • van Eekelen L, Pinckaers H, van dien Brand M, Hebeda KM, Litjens G. Using deep learning for quantification of cellularity and cell lineages in bone marrow biopsies and comparison to normal age-related variation. Pathology. 2022;54(3):318-327.

      van Eekelen L, Pinckaers H, van dien Brand M, Hebeda KM, Litjens G. Using deep learning for quantification of cellularity and cell lineages in bone marrow biopsies and comparison to normal age-related variation. Pathology. 2022;54(3):318-327.

    • Jonas B, Wei A, Recher C, et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97:E299–E303.

      Jonas B, Wei A, Recher C, et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2022;97:E299–E303.

    +